On Monday, Shares of B/E Aerospace Inc (NASDAQ:BEAV), lost -1.05% to $49.10.
B/E Aerospace, will take part in a question and answer “fireside chat” at the Citi 2015 Industrials Conference in Boston on Wednesday, September 16, 2015. The presentation will start at 2:00 p.m. Eastern time.
B/E Aerospace, Inc. designs, manufactures, sells, and services cabin interior products for commercial aircraft and business jets in the United States and internationally. Its Commercial Aircraft segment offers first class, business class, tourist class, and regional aircraft seats, in addition to spares; oxygen storage, distribution, and delivery systems for commercial and business jet aircraft; coffee makers/water boilers, ovens, and refrigeration equipment; and modular lavatory, wastewater, and galley systems.
Shares of DragonWave, Inc.(USA) (NASDAQ:DRWI), inclined 26.32% to $0.240, during its last trading session.
DragonWave, declared updated revenue expectations of about $27.5 million for the second quarter of fiscal year 2016 ended August 31, 2015.
This updates previous guidance offered on July 8, 2015 that sequential quarterly revenue growth would be in the low end of the 30% to 60% range. The sequential quarterly revenue growth for Q2 is now predictable to be about 4%. The variance from our July 8, 2015 outlook was primarily caused by two factors:
- equipment and service orders that were about $3.4 million lower than predictable (about half of these orders are now anticipated to be received in Q3), and
- about $2.8 million of shipments that did not make the Q2 cutoff and slipped to Q3.
A small amount of the variance is due to a large deployment in India that was halted during Q2 as a result of a product issue. While the product issue has now been resolved, the deployment of our product by the affected customer continues to be suspended. DragonWave President and CEO Peter Allen said “Q2 has obviously been a very challenging quarter for DragonWave. We are developing the plan for moving forward and anticipate sharing that plan on our next regularly planned investors’ call.”
DragonWave Inc. provides high-capacity packet microwave solutions that drive next-generation IP networks worldwide. The company designs, develops, markets, and sells proprietary, carrier-grade microwave radio frequency networking equipment that wirelessly transmit broadband voice, video, and other data between two points.
Finally, Cytori Therapeutics Inc (NASDAQ:CYTX), ended its last trade with -6.32% loss, and closed at $0.416.
Cytori Therapeutics, declared the publication of the results from the 12 month clinical follow up of patients enrolled in the Scleradec-I clinical trial from hand dysfunction common in patients with the rare disease scleroderma. The Scleradec-I trial, an investigator-initiated, open-label 12 patient trial, was led by Dr. Brigitte Granel and Dr. Guy Magalon from the Assistance Publique des Hôpitaux de Marseille. The manuscript was published in the journal Rheumatology.
The publication documented that a single treatment with Cytori Cell Therapy™, known as ECCS-50, offered prolonged improvements in patients with impaired hand function due to scleroderma. Specifically, hand function assessed using the validated clinical measure known as the Cochin Hand Function Scale and overall health status using the Scleroderma Health Activity Questionnaire improved from baseline by an average of 51.3% and 46.8%, respectively, at 12 months (p≤0.001 for both). Raynaud’s Condition Score, which measures the incidence and severity of Raynaud’s phenomena, was reduced by 63.2% from baseline at 12 months (p<0.001). Other key findings comprise a 30.5% improvement from baseline in grip strength (p=0.002) and 34.5% improvement from baseline in pain (p=0.052).
Cytori Therapeutics, Inc., a biotechnology company, develops cell therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy compriseing of a heterogeneous population of specialized cells, counting stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
